A new AI-powered risk prediction model assists clinicians in treating cancer patients following a heart attack by combining oncology and cardiovascular data.
Key Details
- 1Researchers at University of Zurich developed ONCO-ACS, an AI-based tool for individualized risk assessment in cancer patients post-heart attack.
- 2Used data from over 1 million heart attack patients, including 47,000 with cancer, from England, Sweden, and Switzerland.
- 3Cancer patients showed a nearly 1 in 3 mortality rate within six months after a heart attack.
- 4ONCO-ACS predicts risks of death, major bleeding, or recurrent cardiac event within six months, using both cancer-related and standard cardiovascular data.
- 5The tool is validated and aims to support tailored decisions regarding catheter-based interventions and antiplatelet therapy.
Why It Matters
This is among the first AI tools designed specifically for the intersection of oncology and cardiology, addressing a major gap in risk prediction for a previously overlooked patient population. It could improve outcomes and inform personalized care strategies in radiology and broader clinical management.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.